Concepedia

Silvana Lanzalone

SL

Statistics

Publications

23

Citations

2.5K

H-Index

18

Active since

1997

Affiliations

Pfizer (Italy)(Current)

Pfizer (United States)

Seoul National University Hospital

Samsung Medical Center

Peter MacCallum Cancer Centre

Silvana Lanzalone is an author at Pfizer (Italy) specializing in medicine, oncology, and pharmacology.

Publications per year

1997–2023

23

Publications

23

Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin et al. · Journal of Clinical Oncology · 2013 · 774 citations · Full text

, , +15

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Jennifer K. Litton, Sara A. Hurvitz, Lida A. Mina et al. · Annals of Oncology · 2020 · 394 citations · Full text

, , +14

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

Sandrine Faivre, Éric Raymond, Éveline Boucher et al. · The Lancet Oncology · 2009 · 291 citations

, , +13

Results of a global phase II study with crizotinib in advanced <i>ALK</i>-positive non-small cell lung cancer (NSCLC).

Dong‐Wan Kim, Myung‐Ju Ahn, Yuankai Shi et al. · Journal of Clinical Oncology · 2012 · 159 citations

, , +15

Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase ii multicentre multinational study

Beat Thürlimann, R. Paridaens, D. Serin et al. · European Journal of Cancer · 1997 · 145 citations

, , +17

1–5 of 23